Levetiracetam
Product Images NDC 63739-158

8 FDA label images from Mckesson Corporation Dba Sky Packaging · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 63739-158). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mckesson Corporation Dba Sky Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Chemical Structure (Levetiracetam 01)

Chemical Structure (Levetiracetam 01)
Chemical structure diagram of levetiracetam showing its molecular connectivity, including a pyrrolidone ring and an ethyl side chain.*
FDA Label Image

Figure 1 (Levetiracetam 02)

Figure 1 (Levetiracetam 02)
A bar chart comparing the percentage of patients for Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day groups. The y-axis shows percentage of patients, while x-axis lists the treatment groups with sample sizes. Values are approximately 7.4%, 37.1%, and 39.6% respectively.*
FDA Label Image

Figure 2 (Levetiracetam 03)

Figure 2 (Levetiracetam 03)
A bar chart comparing the percentage of patients across three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day. The y-axis represents the percentage of patients, and the values are approximately 6.3% for Placebo, 20.8% for Levetiracetam 1000 mg/day, and 35.2% for Levetiracetam 2000 mg/day. Sample sizes are indicated below each group.*
FDA Label Image

Figure 3 (Levetiracetam 04)

Figure 3 (Levetiracetam 04)
A bar chart comparing the percentage of patients for placebo versus Levetiracetam 3000 mg/day. The chart shows approximately 14.4% of patients for placebo (N=104) and 39.4% for Levetiracetam 3000 mg/day (N=180). The y-axis represents the percentage of patients.*
FDA Label Image

Figure 4 (Levetiracetam 05)

Figure 4 (Levetiracetam 05)
A bar graph comparing the percentage of patients between two groups: Placebo (19.6% of 97 patients) and Levetiracetam (44.6% of 101 patients). The y-axis represents the percentage of patients.*
FDA Label Image

Figure 5 (Levetiracetam 06)

Figure 5 (Levetiracetam 06)
Bar chart comparing the percentage of patients responding to Placebo (19.6%, N=51) versus Levetiracetam (43.1%, N=58). A statistical significance marker indicates the Levetiracetam response is significantly higher than placebo.*
FDA Label Image

Figure 6 (Levetiracetam 07)

Figure 6 (Levetiracetam 07)
A bar chart comparing the percentage of patients between two groups: Placebo (N=84) and Levetiracetam (N=79). The Placebo group shows 45.2%, and the Levetiracetam group shows 72.2%, with an asterisk indicating a significant difference.*
FDA Label Image

Principal Display Panel (5 mL Cup Label)

Principal Display Panel (5 mL Cup Label)
Levetiracetam Oral Solution USP 500 mg/5 mL medication label delivering 5 mL per dose. The label includes the NDC 63739-158-70 and states it is for institutional use only, Rx only. Distributed by SKY Packaging, Memphis, TN.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.